Aim:To in vestigate how previous systemic therapy such as an ti-a ngioge nesis can in flue nee can cer imm uno therapy for non-small cell l ung can cer(NSCLC).Methods:A total of 134 patie nts with adva need NSCLC who ...Aim:To in vestigate how previous systemic therapy such as an ti-a ngioge nesis can in flue nee can cer imm uno therapy for non-small cell l ung can cer(NSCLC).Methods:A total of 134 patie nts with adva need NSCLC who were treated with ni volumab were retrospectively reviewed.Correlation between status of prior anti-angiogenesis treatment and clinical characteristics were determined.Impact of prior an ti-a ngioge nesis on therapeutic outcome of ni volumab was in vestigated for tumor efficacy such as progressi on-free survival(PFS).Results:Sixtee n patie nts were treated with at least one an ti-a ngioge nesis age nt prior to ni volumab.The prior use of an tian gioge nesis age nt was associated with stage IV disease,non-squamous histology,and two or more lines of systemic therapy.Media n PFS was sig nifica ntly shorter in the prior an ti-a ngioge nesis group tha n in no prior an ti-a ngioge nesis group(8.3 vs.11.3 weeks,log-rank P 0.006).Multivariate analyses demonstrated that only prior anti-angiogenesis status was associated with worse PFS.There is also a slight trend for worse disease control rate(P 0.101,Fisher's exact test)and overall survival(P 0.200,log-ra nk)in prior an ti-a ngioge nesis group.Conclusion:This retrospective study suggests that prior anti-angiogenesis treatment negatively impacts the therapeutic outcome of immunotherapy in advanced NSCLC.展开更多
文摘Aim:To in vestigate how previous systemic therapy such as an ti-a ngioge nesis can in flue nee can cer imm uno therapy for non-small cell l ung can cer(NSCLC).Methods:A total of 134 patie nts with adva need NSCLC who were treated with ni volumab were retrospectively reviewed.Correlation between status of prior anti-angiogenesis treatment and clinical characteristics were determined.Impact of prior an ti-a ngioge nesis on therapeutic outcome of ni volumab was in vestigated for tumor efficacy such as progressi on-free survival(PFS).Results:Sixtee n patie nts were treated with at least one an ti-a ngioge nesis age nt prior to ni volumab.The prior use of an tian gioge nesis age nt was associated with stage IV disease,non-squamous histology,and two or more lines of systemic therapy.Media n PFS was sig nifica ntly shorter in the prior an ti-a ngioge nesis group tha n in no prior an ti-a ngioge nesis group(8.3 vs.11.3 weeks,log-rank P 0.006).Multivariate analyses demonstrated that only prior anti-angiogenesis status was associated with worse PFS.There is also a slight trend for worse disease control rate(P 0.101,Fisher's exact test)and overall survival(P 0.200,log-ra nk)in prior an ti-a ngioge nesis group.Conclusion:This retrospective study suggests that prior anti-angiogenesis treatment negatively impacts the therapeutic outcome of immunotherapy in advanced NSCLC.
